Stay updated on Durvalumab & Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab & Tremelimumab in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 was added and Revision: v3.4.1 was removed. This is a minor version/metadata update that does not affect the study content or the page’s primary functions.SummaryDifference0.0%

- Check20 days agoChange DetectedThe page now displays Revision: v3.4.1 and removed Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedThe page now includes a glossary toggle and a visible QC status field ('Last Update Submitted that Met QC Criteria'). The previous QC wording was removed/adjusted and versioning text was updated.SummaryDifference0.1%

- Check42 days agoChange DetectedPage revision label updated to Revision: v3.3.4, replacing v3.3.3, as a minor UI/version change. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedUpdated the study page by expanding the Locations section with additional site entries (Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky, Maryland, Michigan, Missouri, Nebraska, New York, North Carolina, Ohio, Tennessee, Utah, Washington, and New Brunswick) and updating the revision to v3.3.3.SummaryDifference0.7%

- Check91 days agoChange DetectedPublications From PubMed section wording was updated to indicate automatic filling from PubMed. Revision labels were updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

Stay in the know with updates to Durvalumab & Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.